No Data
No Data
No Data
No Data
No Data
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
The late-breaking session at the American Academy of Dermatology (AAD) Annual Meeting offers a first look at data from 17 adult and adolescent participants (aged 12-64 years) enrolled in the open-label maximum use arm
BusinesswireMar 10 18:15 ET
Timber Pharmaceuticals Announces Bankruptcy and Investment Risks
TipRanksFeb 22 06:16 ET
Timber Pharmaceuticals Files for Chapter 11 Bankruptcy
TipRanksJan 27 04:05 ET
Timber Pharmaceuticals Announces Official Name Change
TipRanksJan 27 04:05 ET
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
Strategic acquisition to expand pipeline, accelerate growth, and meet unmet needs in medical dermatology. LEO Pharma today announced that it has finalized the acquisition of the strategic asset TMB-001 as well as
BusinesswireJan 23 06:30 ET
Global Lamellar Icthyosis Pipeline Research Report 2023 Featuring Timber Pharmaceuticals, Krystal Biotech, and Janssen
Yahoo FinanceDec 12, 2023 05:03 ET
JESSE JAMES8832OP : .02 support lvl
JESSE JAMES8832OP : 01 support now
No Data
No Data
102765799 : but still no movement whatsoever..